Should MRI be the primary endpoint of phase III trials in MS? No

被引：0
|
作者：
Weinshenker, B. G. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
107
引用
收藏
页码：28 / 28
页数：1
相关论文
共 50 条
  • [41] Closeout of four phase II vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial
    Tavel, JA
    Fosdick, L
    CONTROLLED CLINICAL TRIALS, 2001, 22 (01): : 42 - 48
  • [42] How should phase III therapeutic trials in multiple sclerosis be evaluated: advances and challenges
    Waubant, E
    Goodkin, D
    REVUE NEUROLOGIQUE, 1999, 155 : S7 - S12
  • [43] Should patient enrollment criteria for anti-VEGF phase III trials be reconsidered
    Hanhart, Joel
    Jeon, Sohee
    Tuuminen, Raimo
    JOURNAL OF DIABETES, 2023, 15 (10) : 911 - 912
  • [44] Health-related quality of life (QoL) in randomized phase III trials in oncology: Association between results of QoL, results of primary endpoint and drug approval
    Paratore, Chiara
    Schiavone, Rocco
    Zichi, Clizia
    Caglio, Andrea
    Gamba, Teresa
    Bombaci, Sebastiano
    Vellani, Giorgio
    Marandino, Laura
    Perrone, Francesco
    Di Maio, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Brain and spinal cord atrophy as a primary endpoint in clinical trials
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 70 - 70
  • [46] A new primary efficacy endpoint for specific immunotherapy clinical trials
    Vicaut, E.
    Grouin, J.
    Devillier, P.
    de Beaumont, O.
    Montagut, A.
    Le Gall, M.
    Jean-Alphonse, S.
    ALLERGY, 2009, 64 : 466 - 466
  • [47] Choice of Primary Endpoint for Trials Comparing Balloon Angioplasty and Stenting
    Byrne, Robert A.
    Colleran, Roisin
    JACC-CARDIOVASCULAR INTERVENTIONS, 2021, 14 (06) : 709 - 709
  • [48] Validation of the EAACI recommended combined symptom and medication score as primary endpoint for Phase III in grass allergy
    De Kam, Pieter-Jan
    Zielen, Stefan
    Bernstain, Jonathan
    Berger, Uwe
    Berger, Markus
    Mosges, Ralph
    Shamji, Mohamed
    DuBuske, Lawrence
    Seybold, Marion
    Armfield, Oliver
    Lis, Katarzyna
    Pedragosa, Xavi
    Kramer, Matthias
    Skinner, Murray
    CLINICAL AND EXPERIMENTAL ALLERGY, 2024, 54 (10): : 801 - 801
  • [49] NON-INFERIORITY TRIALS WITH A PRIMARY SURROGATE ENDPOINT: AN INCREASING PHENOTYPE IN CARDIOVASCULAR TRIALS
    Bikdeli, Behnood
    Caraballo-Cordovez, Cesar
    Welsh, John
    Ross, Joseph
    Stone, Gregg
    Krumholz, Harlan M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1838 - 1838
  • [50] Section III - Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism? Presentation I
    Shepherd, J
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (8A): : 88F - 89F
12345